RxDoctor Payments Data

James Walker, MD

Internal Medicine · Athens, ALNPI 1548206659

Payments from drug & device makers

$168in general payments, 2019–2025

Across 9 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$35
  • Biohaven Pharmaceutical Holding Company Ltd.$33
  • Mallinckrodt Hospital Products Inc.$30
  • AstraZeneca$27
  • AbbVie$18
  • Johnson & Johnson$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$168 in reported general payments places this provider in the 35th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$156,902
Medicare patients
547
Services billed
3,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$87,068
OzempicSemaglutide80$85,497
MounjaroTirzepatide57$67,588
JardianceEmpagliflozin31$33,594
XareltoRivaroxaban32$30,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$24,283
FarxigaDapagliflozin Propanediol14$17,243
RybelsusSemaglutide16$17,108
LinzessLinaclotide28$14,552
TrulicityDulaglutide15$14,433
JanuviaSitagliptin Phosphate16$13,658
EntrestoSacubitril/Valsartan17$10,410
Breo ElliptaFluticasone/Vilanterol16$9,936
JanumetSitagliptin Phos/Metformin Hcl13$7,042
NamzaricMemantine Hcl/Donepezil Hcl12$6,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$35$102,60596 claims
PfizerEliquis$12$87,068118 claims
Johnson & JohnsonXarelto$13$30,63532 claims
AbbVieLinzess, Namzaric, Synthroid$18$24,05375 claims
AstraZenecaFarxiga$27$17,24314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →